Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Stereotactic Radiosurgery for Early-Stage Prostate Cancer

  • Chapter
  • First Online:
Image-Guided Stereotactic Radiosurgery

  • 706 Accesses

Abstract

Cancer of the prostate gland has been the most common cancer in men in the Western hemisphere. Not only because of its high incidence or comprehensive treatment costs that transgress each year frontiers but because of its potential mortality, prostate cancer is today a large-scale challenge to the medicine and healthcare systems.

Globally, prostate cancer is the second most frequently diagnosed cancer and the sixth leading cause of cancer death in men.

Stereotactic radiosurgery seems to offer a safe and effective alternative method in relation to surgery, conventional external beam radiotherapy, and brachytherapy.

Data on non-invasive image-guided stereotactic radiosurgery for prostate cancer in its early stages are available. The method is feasible and cost-effective. It could be executed in outpatient setting and the treatment time extremely shorter than all other radiotherapeutic procedures.

Large-scale prospective controlled trials are in need.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.

    Article  PubMed  Google Scholar 

  2. Wolff RF, Ryder S, Bossi A, Briganti A, Crook J, Henry A, et al. A systematic review of randomised controlled trials of radiotherapy for localised prostate cancer. Eur J Cancer. 2015;51(16):2345–67.

    Article  PubMed  Google Scholar 

  3. CancerResearch. Prostate cancer statistics: http://www.cancerresearchuk.org/ (2016) [cited 1 Feb 2016]. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer-heading-Zero.

  4. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.

    Article  PubMed  Google Scholar 

  5. Siegel RL, Fedewa SA, Miller KD, Goding-Sauer A, Pinheiro PS, Martinez-Tyson D, et al. Cancer statistics for Hispanics/Latinos, 2015. CA Cancer J Clin. 2015;65(6):457–80.

    Article  PubMed  Google Scholar 

  6. Walsh S, Roelofs E, Kuess P, Lambin P, Jones B, Georg D, et al. A validated tumor control probability model based on a meta-analysis of low, intermediate, and high-risk prostate cancer patients treated by photon, proton, or carbon-ion radiotherapy. Med Phys. 2016;43(2):734.

    Article  CAS  PubMed  Google Scholar 

  7. Tree AC, van As NJ, Dearnaley DP. Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery versus radiotherapy for clinically-localized prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016. http://dx.doi.org/10.1016/j.eururo.2015.11.010.

  8. Wallis CJ, Saskin R, Choo R, Herschorn S, Kodama RT, Satkunasivam R, et al. Surgery versus radiotherapy for clinically-localized prostate cancer: a systematic review and meta-analysis. Eur Urol. 2015.

    Google Scholar 

  9. Kupelian P, Mehta NH, King C, Steinberg M, Finkelstein SE, Fernandez E. Stereotactic body radiation therapy for prostate cancer: rational and reasonable. Pract Radiat Oncology. 2015;5(3):188–92.

    Article  Google Scholar 

  10. Martinez AA, Demanes J, Vargas C, Schour L, Ghilezan M, Gustafson GS. High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer. Am J Clin Oncol. 2010;33(5):481–8.

    Article  PubMed  Google Scholar 

  11. Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland clinic experience. Int J Radiat Oncol Biol Phys. 2007;68(5):1424–30.

    Article  PubMed  Google Scholar 

  12. Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A. Impact of image guidance on outcomes after external beam radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(4):1146–50.

    Article  PubMed  Google Scholar 

  13. Thames HD, Kuban D, Levy LB, Horwitz EM, Kupelian P, Martinez A, et al. The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 Men treated between 1987 and 1995. Radiother Oncol : J Eur Soc Ther Radiol Oncol. 2010;96(1):6–12.

    Article  Google Scholar 

  14. Pollack A, Walker G, Horwitz EM, Price R, Feigenberg S, Konski AA, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol : Off J Am Soc Clin Oncol. 2013;31(31):3860–8.

    Article  Google Scholar 

  15. Lee WR. Prostate cancer and the hypofractionation hypothesis. J Clin Oncol : Off J Am Soc Clin Oncol. 2013;31(31):3849–51.

    Article  Google Scholar 

  16. Ghilezan M, Yan D, Martinez A. Adaptive radiation therapy for prostate cancer. Semin Radiat Oncol. 2010;20(2):130–7.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Fonteyne V, Soete G, Arcangeli S, De Neve W, Rappe B, Storme G, et al. Hypofractionated high-dose radiation therapy for prostate cancer: long-term results of a multi-institutional phase II trial. Int J Radiat Oncol Biol Phys. 2012;84(4):e483–90.

    Article  PubMed  Google Scholar 

  18. Chalasani V, Martinez CH, Williams AK, Kwan K, Chin JL. Histological changes in the human prostate after radiotherapy and salvage high intensity focused ultrasound. Can Urol Assoc J = Journal de l’Association des urologues du Canada. 2010;4(4):E100–2.

    Google Scholar 

  19. Cabrera AR, Lee WR. Hypofractionation for clinically localized prostate cancer. Semin Radiat Oncol. 2013;23(3):191–7.

    Article  PubMed  Google Scholar 

  20. Bekelman JE, Suneja G, Guzzo T, Pollack CE, Armstrong K, Epstein AJ. Effect of practice integration between urologists and radiation oncologists on prostate cancer treatment patterns. J Urol. 2013;190(1):97–101.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Arcangeli S, Strigari L, Gomellini S, Saracino B, Petrongari MG, Pinnaro P, et al. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012;84(5):1172–8.

    Article  PubMed  Google Scholar 

  22. Arcangeli S, Scorsetti M, Alongi F. Will SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review. Crit Rev Oncol Hematol. 2012;84(1):101–8.

    Article  Google Scholar 

  23. Kupelian PA, Lee C, Langen KM, Zeidan OA, Manon RR, Willoughby TR, et al. Evaluation of image-guidance strategies in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(4):1151–7.

    Article  PubMed  Google Scholar 

  24. Kupelian PA, Ciezki J, Reddy CA, Klein EA, Mahadevan A. Effect of increasing radiation doses on local and distant failures in patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;71(1):16–22.

    Article  PubMed  Google Scholar 

  25. Kupelian P, Meyer JL. Prostate cancer: image guidance and adaptive therapy. Front Radiat Ther Oncol. 2007;40:289–314.

    Article  PubMed  Google Scholar 

  26. Zelefsky MJ, Lee WR, Zietman A, Khalid N, Crozier C, Owen J, et al. Evaluation of adherence to quality measures for prostate cancer radiotherapy in the United States: results from the Quality Research in Radiation Oncology (QRRO) survey. Pract Radiat Oncol. 2013;3(1):2–8.

    Article  PubMed  Google Scholar 

  27. Wu QJ, Li T, Yuan L, Yin FF, Lee WR. Single institution’s dosimetry and IGRT analysis of prostate SBRT. Radiat Oncol. 2013;8:215.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Martinez CH, Chalasani V, Lim D, Nott L, Al-Bareeq RJ, Wignall GR, et al. Effect of prostate gland size on the learning curve for robot-assisted laparoscopic radical prostatectomy: does size matter initially? J Endourol/Endourol Soc. 2010;24(2):261–6.

    Article  Google Scholar 

  29. Stoyanova R, Sandler K, Pollack A. Delineation and visualization of prostate cancer in multiparametric MRI. Pract Radiat Oncol. 2013;3(2 Suppl 1):S30–1.

    Article  CAS  PubMed  Google Scholar 

  30. King CR, Freeman D, Kaplan I, Fuller D, Bolzicco G, Collins S, et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncology : J Eur Soc Ther Radiol Oncol. 2013;109(2):217–21.

    Article  Google Scholar 

  31. King CR, Collins S, Fuller D, Wang PC, Kupelian P, Steinberg M, et al. Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials. Int J Radiat Oncol Biol Phys. 2013;87(5):939–45.

    Article  PubMed  Google Scholar 

  32. Boike TP, Lotan Y, Cho LC, Brindle J, DeRose P, Xie XJ, et al. Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol : Off J Am Soc Clin Oncol. 2011;29(15):2020–6.

    Article  Google Scholar 

  33. Violette PD, Agoritsas T, Alexander P, Riikonen J, Santti H, Agarwal A, et al. Decision aids for localized prostate cancer treatment choice: systematic review and meta-analysis. CA Cancer J Clin. 2015;65(3):239–51.

    Article  PubMed  Google Scholar 

  34. Zhang X, Wu J. Prognostic role of microRNA-145 in prostate cancer: a systems review and meta-analysis. Prostate Int. 2015;3(3):71–4.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Wallis CJ, Mahar AL, Choo R, Herschorn S, Kodama RT, Shah PS, et al. Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. BMJ. 2016;352:i851.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Travis RC, Appleby PN, Martin RM, Holly JM, Albanes D, Black A, et al. A meta-analysis of individual participant data reveals an association between circulating levels of IGF-I and prostate cancer risk. Cancer Res. 2016.

    Google Scholar 

  37. Zhang X, Zhou G, Sun B, Zhao G, Liu D, Sun J, et al. Impact of obesity upon prostate cancer-associated mortality: a meta-analysis of 17 cohort studies. Oncol Lett. 2015;9(3):1307–12.

    PubMed  Google Scholar 

  38. Zhai L, Cheng S, Zhang D. Dietary carbohydrate and prostate cancer risk: a meta-analysis. Nutr Cancer. 2015;67(4):594–602.

    Article  CAS  Google Scholar 

  39. Sommariva S, Tarricone R, Lazzeri M, Ricciardi W, Montorsi F. Prognostic value of the cell cycle progression score in patients with prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;69(1):107–15.

    Article  PubMed  Google Scholar 

  40. Raval AD, Thakker D, Negi H, Vyas A, Salkini MW. Association between statins and clinical outcomes among men with prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2016;19:151–62.

    Article  CAS  PubMed  Google Scholar 

  41. Petrelli F, Vavassori I, Cabiddu M, Coinu A, Ghilardi M, Borgonovo K, et al. Predictive factors for reclassification and relapse in prostate cancer eligible for active surveillance: a systematic review and meta-analysis. Urology. 2016;91:136–42.

    Article  PubMed  Google Scholar 

  42. Penson DF. Re: intermittent vs continuous androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. J Urol. 2016;195(2):353–4.

    Google Scholar 

  43. Morote J, Regis L, Celma A, Planas J. Measurement of serum testosterone during androgenic suppression in patients with prostate cancer: a systematic review. Actas Urol Esp. 2016.

    Google Scholar 

  44. Mao Y, Xu X, Zheng X, Xie L. Reduced risk of prostate cancer in childless Men as compared to fathers: a systematic review and meta-analysis. Sci Rep. 2016;6:19210.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Zhou CK, Sutcliffe S, Welsh J, Mackinnon K, Kuh D, Hardy R, et al. Is birthweight associated with total and aggressive/lethal prostate cancer risks? A systematic review and meta-analysis. Br J Cancer. 2016;114(7):839–48.

    Article  CAS  PubMed  Google Scholar 

  46. Zhong S, Yan X, Wu Y, Zhang X, Chen L, Tang J, et al. Body mass index and mortality in prostate cancer patients: a dose-response meta-analysis. Prostate Cancer Prostatic Dis. 2016;19:122–31.

    Article  CAS  PubMed  Google Scholar 

  47. Lewis-Mikhael AM, Bueno-Cavanillas A, Ofir Guiron T, Olmedo-Requena R, Delgado-Rodriguez M, Jimenez-Moleon JJ. Occupational exposure to pesticides and prostate cancer: a systematic review and meta-analysis. Occup Environ Med. 2016;73(2):134–44.

    Article  PubMed  Google Scholar 

  48. Chen Q, Chen T, Shi W, Zhang T, Zhang W, Jin Z, et al. Adult weight gain and risk of prostate cancer: a dose-response meta-analysis of observational studies. Int J Cancer Journal international du cancer. 2016;138(4):866–74.

    Article  CAS  PubMed  Google Scholar 

  49. Stopsack KH, Ziehr DR, Rider JR, Giovannucci EL. Metformin and prostate cancer mortality: a meta-analysis. Cancer Causes Control. 2016;27(1):105–13.

    Article  PubMed  Google Scholar 

  50. Teleni L, Chan RJ, Chan A, Isenring EA, Vela I, Inder WJ, et al. Exercise improves quality of life in androgen deprivation therapy-treated prostate cancer: systematic review of randomised controlled trials. Endocr Relat Cancer. 2016;23(2):101–12.

    Article  PubMed  Google Scholar 

  51. Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, et al. Meta-analysis evaluating the impact of site of metastasis on overall survival in Men with castration-resistant prostate cancer. J Clin Oncol: Off J Am Soc Clin Oncol. 2016.

    Google Scholar 

  52. Lei JH, Liu LR, Wei Q, Song TR, Yang L, Meng Y, et al. Androgen-deprivation therapy alone versus combined with radiation therapy or chemotherapy for nonlocalized prostate cancer: a systematic review and meta-analysis. Asian J Androl. 2016;18(1):102–7.

    Article  PubMed  Google Scholar 

  53. Helgstrand JT, Berg KD, Lippert S, Brasso K, Røder MA. Systematic review: does endocrine therapy prolong survival in patients with prostate cancer? Scand J Urol. 2016;50(3):135–43. doi: 10.3109/21681805.2016.1142472. Epub 2016 Feb 23.

    Google Scholar 

  54. Baker H, Wellman S, Lavender V. Functional quality-of-life outcomes reported by men treated for localized prostate cancer: a systematic literature review. Oncol Nurs Forum. 2016;43(2):199–218.

    Article  PubMed  Google Scholar 

  55. Yang L, Xie S, Feng X, Chen Y, Zheng T, Dai M, et al. Worldwide prevalence of human papillomavirus and relative risk of prostate cancer: a meta-analysis. Sci Rep. 2015;5:14667.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Yan J, Wang X, Tao H, Deng Z, Yang W, Lin F. Meta-analysis of the relationship between XRCC1-Arg399Gln and Arg280His polymorphisms and the risk of prostate cancer. Sci Rep. 2015;5:9905.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Xuan G, Hui Y, Fang H. The association of XRCC3 Thr241Met genetic variant with risk of prostate cancer: a meta-analysis. Afr Health Sci. 2015;15(1):117–22.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Xu C, Han FF, Zeng XT, Liu TZ, Li S, Gao ZY. Fat intake is not linked to prostate cancer: a systematic review and dose-response meta-analysis. PLoS One. 2015;10(7):e0131747.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Wu GF, Zhang XL, Luo ZG, Yan JJ, Pan SH, Ying XR, et al. Metformin therapy and prostate cancer risk: a meta-analysis of observational studies. Int J Clin Exp Med. 2015;8(8):13089–98.

    PubMed  PubMed Central  Google Scholar 

  60. Kim HJ, Phak JH, Kim WC. Clinical outcomes of whole pelvis radiotherapy and stereotactic body radiotherapy boost for intermediate- and high-risk prostate cancer. Asia Pac J Clin Oncol. 2016.

    Google Scholar 

  61. Young SM, Bansal P, Vella ET, Finelli A, Levitt C, Loblaw A. Systematic review of clinical features of suspected prostate cancer in primary care. Can Fam Physician Medecin de famille canadien. 2015;61(1):e26–35.

    PubMed  Google Scholar 

  62. Sanchez-Gomez LM, Polo-deSantos M, Rodriguez-Melcon JI, Angulo JC, Luengo-Matos S. Hypofractionated radiation therapy versus conventional radiation therapy in prostate cancer: a systematic review of its safety and efficacy. Actas Urol Esp. 2015;39(6):367–74.

    Article  CAS  PubMed  Google Scholar 

  63. Sharieff W, Greenspoon JN, Dayes I, Chow T, Wright J, Lukka H. The technique, resources and costs of stereotactic body radiotherapy of prostate cancer: a comparison of dose regimens and delivery systems. Technol Cancer Res Treat. 2016;15(1):171–8.

    PubMed  Google Scholar 

  64. Tan TJ, Siva S, Foroudi F, Gill S. Stereotactic body radiotherapy for primary prostate cancer: a systematic review. J Med Imaging Radiat Oncol. 2014;58(5):601–11.

    Article  PubMed  Google Scholar 

  65. Zaorsky NG, Palmer JD, Hurwitz MD, Keith SW, Dicker AP, Den RB. What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation. Radiother Oncol : J Eur Soc Ther Radiol Oncol. 2015;115(3):295–300.

    Article  Google Scholar 

  66. Woo JA, Chen LN, Wang H, Cyr RA, Bhattasali O, Kim JS, et al. Stereotactic body radiation therapy for prostate cancer: what is the appropriate patient-reported outcome for clinical trial design? Front Oncol. 2015;5:77.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Pontoriero A, Iati G, Mondello S, Midili F, Siragusa C, Brogna A, et al. High-dose robotic stereotactic body radiotherapy in the treatment of patients with prostate cancer: preliminary results in 26 patients. Technol Cancer Res Treat. 2016;15(1):179–85.

    CAS  PubMed  Google Scholar 

  68. Seymour ZA, Chang AJ, Zhang L, Kirby N, Descovich M, Roach 3rd M, et al. Dose-volume analysis and the temporal nature of toxicity with stereotactic body radiation therapy for prostate cancer. Pract Radiat Oncol. 2015;5(5):e465–72.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Charité School of Medicine, Berlin, Germany

    Harun Badakhshi

Authors
  1. Harun Badakhshi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Badakhshi, H. (2016). Stereotactic Radiosurgery for Early-Stage Prostate Cancer. In: Image-Guided Stereotactic Radiosurgery. Springer, Cham. https://doi.org/10.1007/978-3-319-39189-2_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-39189-2_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-39187-8

  • Online ISBN: 978-3-319-39189-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation